Skip to content
PoliticalRepoPoliticalRepo

Ireland · Question · written

PQ 3790

3790. Deputy Seán Crowe asked the Minister for Health the status of sepiapterin for the treatment of phenylketonuria (PKU) in Ireland; whether a formal pricing and reimbursement application has been submitted to the HSE by an organisation (details supplied); if not, the engagement that has taken place between the HSE and the company on the matter; the steps being taken to expedite access to this treatment; the indicative timeline for assessment and reimbursement once an application is received; the interim or early access arrangements available to eligible patients in the absence of reimbursement; and if she will make a statement on the matter. [62910/26]

askedIreland· Dáil Éireann· EN

Introduced

7 September 2026

Last action

7 September 2026 · Clinical Trials

Status

written

Sponsors

Crowe, Seán.

Subjects

Discovery layer

Source updated

7 September 2026

Summary

3790. Deputy Seán Crowe asked the Minister for Health the status of sepiapterin for the treatment of phenylketonuria (PKU) in Ireland; whether a formal pricing and reimbursement application has been submitted to the HSE by an organisation (details supplied); if not, the engagement that has taken place between the HSE and the company on the matter; the steps being taken to expedite access to this treatment; the indicative timeline for assessment and reimbursement once an application is received; the interim or early access arrangements available to eligible patients in the absence of reimbursement; and if she will make a statement on the matter. [62910/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 7 September 2026

    Clinical Trials

    3790. Deputy Seán Crowe asked the Minister for Health the status of sepiapterin for the treatment of phenylketonuria (PKU) in Ireland; whether a formal pricing and reimbursement application has been submitted to the HSE by an organisation (details supplied); if not, the engagement that has taken place between the HSE and the company on the matter; the steps being taken to expedite access to this treatment; the indicative timeline for assessment and reimbursement once an application is received; the interim or early access arrangements available to eligible patients in the absence of reimbursement; and if she will make a statement on the matter. [62910/26]

    Source: written

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

Clinical Trials

View fileDownload file

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.